Form 4: Apogee Therapeutics Director Nimish Shah Granted Stock Options

Apogee Therapeutics, Inc. Director Nimish P. Shah was granted 14,461 stock options with an exercise price of $41.66, vesting one year from the grant date of June 17, 2025.

Summary

• Nimish P. Shah, a Director of Apogee Therapeutics, Inc. (APGE), was granted stock options.
• The grant date for these options was June 17, 2025.
• The options are for the right to purchase 14,461 shares of Apogee Therapeutics' common stock.
• The exercise price for these options is $41.66 per share.
• The options will vest on the one-year anniversary of the grant date, which is June 17, 2026, contingent on Mr. Shah's continued service to the company.
• The expiration date for these options is June 17, 2035.
• While directly held, the options and underlying shares are for the sole benefit of VR Management, LLC, and Mr. Shah must exercise them only upon the Management Company's direction.
• Mr. Shah disclaims beneficial ownership of the shares except to the extent of his pecuniary interest through VR Management, LLC.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with the company's long-term performance, indicating a positive incentive structure.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a standard equity compensation practice for directors in publicly traded companies, aiming to align their interests with long-term shareholder value. Such grants are common across various industries, including biotechnology, to incentivize leadership.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, similar to compensation structures seen at companies like Moderna (MRNA) or BioNTech (BNTX), where equity incentives are used to retain talent and align leadership with company performance. The specific size and exercise price of the grant would typically be benchmarked against peer group compensation data, though such data is not provided in this filing.

Related Party Transactions

• The stock options and underlying shares are held for the sole benefit of VR Management, LLC, and the reporting person must exercise them only upon the Management Company's direction.
• The reporting person is deemed an indirect beneficial owner through his interest in VR Management, LLC but disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholder value creation, potentially leading to improved long-term performance.

Next Steps

• The stock options are scheduled to vest on June 17, 2026, contingent on the director's continued service to the company.

Key Dates

Keywords

Apogee Therapeutics, APGE, Nimish Shah, stock options, director compensation, SEC Form 4, insider transaction, equity grant